Maven Securities’s Lineage Cell Therapeutics LCTX Stock Holding History

Maven Securities’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-13,185	Closed	-$30K	–	1195
2021 Q1	$30K	Buy	+13,185	New	+$31.7K	﹤0.01%	1124

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Maven Securities's LCTX Position: Q2 2021 in Review

Maven Securities sold out of Lineage Cell Therapeutics (LCTX) in Q2 2021, closing a stake of 13,185 shares — an estimated $30K sold.

Maven Securities first reported a position in LCTX in Q1 2021 and held it in 1 quarter. The position peaked at $30K in Q1 2021. 115 funds tracked by Wall St. Rank hold LCTX as of Q2 2021.

Maven Securities reported no remaining Lineage Cell Therapeutics position as of Q2 2021 after selling out during the quarter.
Maven Securities sold 13,185 Lineage Cell Therapeutics shares in Q2 2021, an estimated $30K.
Maven Securities first reported a position in Lineage Cell Therapeutics in Q1 2021 and held it in 1 quarter.
Maven Securities's Lineage Cell Therapeutics position peaked at $30K in Q1 2021.
115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.